Is GANX or ABEO more profitable?

Abeona Therapeutics' return on equity of -41.69% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Abeona Therapeutics N/A -41.69% -30.36%

Does the media favor GANX or ABEO?

In the previous week, Gain Therapeutics and Gain Therapeutics both had 9 articles in the media. Gain Therapeutics' average media sentiment score of 0.27 beat Abeona Therapeutics' score of 0.21 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, GANX or AGEN?

Agenus has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gain Therapeutics $50K 1,588.50 -$20.16M -$0.50 N/A Agenus $114.20M 3.25 $120K $2.58 3.19

Is GANX or AGEN more profitable?

Agenus has a net margin of 69.33% compared to Gain Therapeutics' net margin of 0.00%. Agenus' return on equity of -47.68% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Agenus 69.33% -47.68% 57.73%

Does the media favor GANX or AGEN?

In the previous week, Gain Therapeutics had 4 more articles in the media than Agenus. MarketBeat recorded 9 mentions for Gain Therapeutics and 5 mentions for Agenus. Gain Therapeutics' average media sentiment score of 0.27 beat Agenus' score of -0.28 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agenus 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is IMRX or GANX more profitable?

Immuneering's return on equity of -27.15% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Gain Therapeutics N/A -161.59% -118.36%

Does the media refer more to IMRX or GANX?

In the previous week, Gain Therapeutics had 8 more articles in the media than Immuneering. MarketBeat recorded 9 mentions for Gain Therapeutics and 1 mentions for Immuneering. Gain Therapeutics' average media sentiment score of 0.27 beat Immuneering's score of -0.64 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Gain Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GANX or IRD?

In the previous week, Gain Therapeutics had 3 more articles in the media than Opus Genetics. MarketBeat recorded 9 mentions for Gain Therapeutics and 6 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.66 beat Gain Therapeutics' score of 0.27 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gain Therapeutics (GANX) Competitors

$1.82 +0.03 (+1.68%)

As of 04:00 PM Eastern

Compare

GANX vs. ABEO, AGEN, STRO, IMRX, and IRD

Should you buy Gain Therapeutics stock or one of its competitors? Gain Therapeutics's main competitors and comparable companies include Abeona Therapeutics (ABEO), Agenus (AGEN), Sutro Biopharma (STRO), Immuneering (IMRX), and Opus Genetics (IRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gain Therapeutics compare to Abeona Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Gain Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 312.09%. Abeona Therapeutics has a consensus price target of $19.33, indicating a potential upside of 226.03%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Gain Therapeutics and Gain Therapeutics both had 9 articles in the media. Gain Therapeutics' average media sentiment score of 0.27 beat Abeona Therapeutics' score of 0.21 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gain Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abeona Therapeutics has higher revenue and earnings than Gain Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A
Abeona Therapeutics	$5.82M	58.26	$71.18M	-$1.09	N/A

Abeona Therapeutics' return on equity of -41.69% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Summary

Gain Therapeutics and Abeona Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Gain Therapeutics compare to Agenus?

Gain Therapeutics (NASDAQ:GANX) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Gain Therapeutics currently has a consensus target price of $7.50, indicating a potential upside of 312.09%. Agenus has a consensus target price of $19.50, indicating a potential upside of 136.65%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Agenus has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A
Agenus	$114.20M	3.25	$120K	$2.58	3.19

Gain Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Agenus has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Agenus has a net margin of 69.33% compared to Gain Therapeutics' net margin of 0.00%. Agenus' return on equity of -47.68% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Agenus	69.33%	-47.68%	57.73%

In the previous week, Gain Therapeutics had 4 more articles in the media than Agenus. MarketBeat recorded 9 mentions for Gain Therapeutics and 5 mentions for Agenus. Gain Therapeutics' average media sentiment score of 0.27 beat Agenus' score of -0.28 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agenus	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Agenus beats Gain Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Gain Therapeutics compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Gain Therapeutics had 9 more articles in the media than Sutro Biopharma. MarketBeat recorded 9 mentions for Gain Therapeutics and 0 mentions for Sutro Biopharma. Gain Therapeutics' average media sentiment score of 0.27 beat Sutro Biopharma's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sutro Biopharma	Neutral
Gain Therapeutics	Neutral

Gain Therapeutics has lower revenue, but higher earnings than Sutro Biopharma. Gain Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	3.32	-$191.09M	-$11.97	N/A
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A

Sutro Biopharma currently has a consensus target price of $47.30, suggesting a potential upside of 130.28%. Gain Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 312.09%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Gain Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Gain Therapeutics	N/A	-161.59%	-118.36%

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sutro Biopharma has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Summary

Sutro Biopharma beats Gain Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Gain Therapeutics compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Immuneering presently has a consensus target price of $17.50, suggesting a potential upside of 247.22%. Gain Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 312.09%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Gain Therapeutics had 8 more articles in the media than Immuneering. MarketBeat recorded 9 mentions for Gain Therapeutics and 1 mentions for Immuneering. Gain Therapeutics' average media sentiment score of 0.27 beat Immuneering's score of -0.64 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Gain Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuneering's return on equity of -27.15% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Gain Therapeutics	N/A	-161.59%	-118.36%

67.7% of Immuneering shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 14.9% of Immuneering shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gain Therapeutics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A

Immuneering has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Summary

Gain Therapeutics beats Immuneering on 8 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Opus Genetics?

Gain Therapeutics (NASDAQ:GANX) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Gain Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Gain Therapeutics' return on equity of -161.59% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Gain Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 312.09%. Opus Genetics has a consensus price target of $10.69, suggesting a potential upside of 132.44%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Gain Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Gain Therapeutics has higher earnings, but lower revenue than Opus Genetics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A
Opus Genetics	$14.20M	26.77	-$49.59M	-$1.35	N/A

In the previous week, Gain Therapeutics had 3 more articles in the media than Opus Genetics. MarketBeat recorded 9 mentions for Gain Therapeutics and 6 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.66 beat Gain Therapeutics' score of 0.27 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Opus Genetics beats Gain Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GANX vs. The Competition

Export

Metric	Gain Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$78.12M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-3.64	12.66	273.28	25.38
Price / Sales	1,588.50	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	7.00	16.29	12.89	6.14
Net Income	-$20.16M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-1.62%	-1.37%	-0.33%	-1.47%
1 Month Performance	4.00%	11.07%	6.51%	2.47%
1 Year Performance	-5.21%	53.71%	25.19%	15.84%

Gain Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GANX Gain Therapeutics	2.4286 of 5 stars	$1.82 +1.7%	$7.50 +312.1%	-6.3%	$78.12M	$50K	N/A	20	News Coverage Analyst Forecast Analyst Revision
ABEO Abeona Therapeutics	2.1038 of 5 stars	$6.21 +2.5%	$19.33 +211.3%	-13.1%	$346.54M	$5.82M	N/A	90
AGEN Agenus	3.5137 of 5 stars	$8.36 +9.0%	$19.50 +133.3%	+94.5%	$345.31M	$114.20M	3.24	440
STRO Sutro Biopharma	2.4387 of 5 stars	$21.44 +4.6%	$47.30 +120.6%	+115.2%	$339.75M	$102.48M	N/A	240
IMRX Immuneering	3.1813 of 5 stars	$5.23 +1.0%	$17.50 +234.6%	-16.2%	$335.13M	N/A	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gain Therapeutics (GANX) Competitors

GANX vs. ABEO, AGEN, STRO, IMRX, and IRD

How does Gain Therapeutics compare to Abeona Therapeutics?

Summary

How does Gain Therapeutics compare to Agenus?

Summary

How does Gain Therapeutics compare to Sutro Biopharma?

Summary

How does Gain Therapeutics compare to Immuneering?

Summary

How does Gain Therapeutics compare to Opus Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gain Therapeutics (GANX) Competitors

GANX vs. ABEO, AGEN, STRO, IMRX, and IRD

How does Gain Therapeutics compare to Abeona Therapeutics?

Do analysts prefer GANX or ABEO?

Does the media favor GANX or ABEO?

Which has more risk & volatility, GANX or ABEO?

Do insiders and institutionals hold more shares of GANX or ABEO?

Which has stronger earnings & valuation, GANX or ABEO?

Is GANX or ABEO more profitable?

Summary

How does Gain Therapeutics compare to Agenus?

Do insiders and institutionals believe in GANX or AGEN?

Do analysts rate GANX or AGEN?

Which has preferable valuation and earnings, GANX or AGEN?

Which has more risk & volatility, GANX or AGEN?

Is GANX or AGEN more profitable?

Does the media favor GANX or AGEN?

Summary

How does Gain Therapeutics compare to Sutro Biopharma?

Does the media favor STRO or GANX?

Which has better earnings and valuation, STRO or GANX?

Do analysts recommend STRO or GANX?

Is STRO or GANX more profitable?

Do insiders & institutionals believe in STRO or GANX?

Which has more risk & volatility, STRO or GANX?

Summary

How does Gain Therapeutics compare to Immuneering?

Do analysts prefer IMRX or GANX?

Does the media refer more to IMRX or GANX?

Is IMRX or GANX more profitable?

Do institutionals and insiders believe in IMRX or GANX?

Which has higher valuation and earnings, IMRX or GANX?

Which has more volatility & risk, IMRX or GANX?

Summary

How does Gain Therapeutics compare to Opus Genetics?

Is GANX or IRD more profitable?

Do analysts prefer GANX or IRD?

Which has more volatility and risk, GANX or IRD?

Which has better valuation and earnings, GANX or IRD?

Does the media prefer GANX or IRD?

Do institutionals & insiders hold more shares of GANX or IRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools